OLEMA PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$2.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$75.00K, a 104.04% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$2.60M.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $4.46M, a 134.14% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$347.00K, a 334.46% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $5.42M, a 1162.94% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $429.00K.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$694.00K, a 135.43% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.96M, a 4797.50% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.67M 10-Q · filed 2026-08-10 | $1.79M derived: sum of 3 quarters · filed 2026-08-10 | $1.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.60M 10-Q · filed 2026-05-12 | $1.86M derived: sum of 2 quarters · filed 2026-05-12 | $1.51M derived: sum of 3 quarters · filed 2026-05-12 | $3.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $4.11M derived: sum of 2 quarters · filed 2026-03-16 | $5.97M derived: sum of 3 quarters · filed 2026-08-10 | $5.42M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$347.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.51M derived: sum of 2 quarters · filed 2026-08-10 | $960.00K 10-Q · filed 2025-11-10 | $2.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.31M 10-Q · filed 2026-08-10 | $3.21M derived: sum of 3 quarters · filed 2026-08-10 | $3.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$549.00K 10-Q · filed 2026-05-12 | $1.35M derived: sum of 2 quarters · filed 2026-05-12 | $1.50M derived: sum of 3 quarters · filed 2026-05-12 | $1.47M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.05M derived: sum of 2 quarters · filed 2026-03-16 | $2.02M derived: sum of 3 quarters · filed 2026-03-16 | $429.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $118.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.48M 10-Q · filed 2025-11-10 | -$1.88M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.62M 10-Q · filed 2025-08-11 | -$2.02M derived: sum of 3 quarters · filed 2025-08-11 | -$1.90M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$1.59M 10-Q · filed 2025-05-13 | -$1.99M derived: sum of 2 quarters · filed 2025-05-13 | -$1.87M derived: sum of 3 quarters · filed 2025-05-13 | -$1.25M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$281.00K derived: sum of 2 quarters · filed 2025-03-18 | $341.00K derived: sum of 3 quarters · filed 2025-03-18 | -$694.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $742.00K derived: sum of 2 quarters · filed 2024-11-12 | -$293.00K 10-Q · filed 2024-11-12 | $1.73M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $622.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$413.00K 10-Q · filed 2024-08-06 | $1.61M derived: sum of 3 quarters · filed 2024-08-06 | $1.75M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.03M 10-Q · filed 2024-05-08 | $985.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.13M derived: sum of 3 quarters · filed 2024-05-08 | $1.10M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $2.16M derived: sum of 2 quarters · filed 2024-03-11 | $2.13M derived: sum of 3 quarters · filed 2024-03-11 | $1.96M 10-K · filed 2024-03-11 |
| 2022-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $111.00K derived: sum of 2 quarters · filed 2023-11-07 | -$61.00K 10-Q · filed 2023-11-07 | $1.21M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$204.00K 10-Q · filed 2023-08-08 | $1.07M derived: sum of 3 quarters · filed 2023-08-08 | $714.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$172.00K 10-Q · filed 2023-05-09 | $1.10M derived: sum of 2 quarters · filed 2023-05-09 | $746.00K derived: sum of 3 quarters · filed 2023-05-09 | $159.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $918.00K derived: sum of 2 quarters · filed 2023-03-09 | $331.00K derived: sum of 3 quarters · filed 2023-03-09 | $40.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$354.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$941.00K derived: sum of 2 quarters · filed 2022-11-08 | -$1.23M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$587.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$878.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$291.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $3.55M 10-K · filed 2022-02-28 | |||
| 2020-06-30 | -$205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $185.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $390.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$58.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |